<DOC>
	<DOC>NCT02426151</DOC>
	<brief_summary>To Compare Pharmacokinetic and Pharmacodynamic Profiles of BEPO-A and REPO-A in Healthy Male Subjects</brief_summary>
	<brief_title>Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects</brief_title>
	<detailed_description>To Compare Pharmacokinetic and Pharmacodynamic Profiles of EPO (BEPO-A (4000 IU)) and EPO (REPO-A (4000 IU)) in Healthy Male Subjects</detailed_description>
	<criteria>Agree to all the purposes of the study by signing and dating the Informed Consent; Male, aged between 19 and 40 years, clinically healthy; BMI between 19 and 28; 90 mmHg ≤ SBP &lt;140 mmHg, 50 mmHg ≤ DBP &lt; 85 mmHg Hemoglobin &lt;13 g / dL Ferritin &lt;20 ng/mL or TIBC &gt; 360 ug/ dL Vitamin B12 &lt; 200 pg/mL or floate &lt; 4 ng/mL %reticulpcyte &gt; 3% platelet &lt; 100,000/ul or &gt; 400,000/ul GFR &lt; 60mL/min/1.73m2 Going to or during treatment of the tumor Clinical history of allergy of biological products derived from mammalian albumin or any component of the formulation Clinical history of autoimmune or hereditary anemia A Positive reaction in the nicotine tests Principal Investigator of the study criteria.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>